NCT03720457View on ClinicalTrials.gov

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2023

Conditions
CD19-positiveDiffuse Large B-cell LymphomaFollicular Lymphoma
Interventions
DRUG

Human CD19 targeted T Cells Injection

Autologous genetically modified anti-CD19 CAR transduced T cells

Trial Locations (3)

200000

RECRUITING

Fudan University Zhongshan Hospital, Shanghai

325003

RECRUITING

The First Affilicated Hospital of Wenzhou Medical University, Wenzhou

330006

RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

Sponsors
All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY